more_reports

Pharma Innovator Unlocks Multi-Disease Treatment Potential

Research Report
  ()
Quince Therapeutics Inc. is "positioned for a transformative year" in 2025 with a solid cash position of US$47.8 million as of the third quarter of 2024. Find out why one analyst gives the stock a Buy rating.
Tags: Biotechnology / Pharmaceuticals

Drug Innovator Launches Pivotal Cancer Trial Breakthrough

Research Report
  ()
Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ) has the potential to generate hundreds of millions of dollars over the next decade with its drug candidates, an H.C. Wainwright & Co. analyst wrote in a January 2 research note.
Tags: Biotechnology / Pharmaceuticals

Miami Biopharma Sells Part of Business and Begins New Clinical Trial

Research Report
  ()
Miami biopharmaceutical company Veru Inc. (VERU:NASDAQ) recently sold its FC2 Female Condom business for US$18 million, and has begun enrolling patients for its The Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for sarcopenic obesity. Read on to see why one analyst gives this company a Buy rating.
Tags: Biotechnology / Pharmaceuticals

Analyst Sees Major Growth for Biopharma With Weight-Loss Drug

Research Report
  ()
Recent successes of weight-loss drugs like Ozempic and Wegovy have led H.C. Wainwright & Co. Analyst Ed Arce to be "intrigued" by MetaVia Inc.'s (MTVA:NASDAQ) new drug candidate.
Tags: Biotechnology / Pharmaceuticals

Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug

Research Report
  ()
NewAmsterdam Pharma Company N.V.'s (NAMS:NASDAQ) drug obicetrapib is a "once-in-a-generation" drug for cardiovascular disease, an analyst wrote in a research note while initiating coverage on the company. See what rating the stock got and its price per share target.
Tags: Biotechnology / Pharmaceuticals

Parkinson's Treatment Advancements: Clinical Trials Begin for Potential New Therapy

  ()
Gain Therapeutics Inc. (GANX:NASDAQ) has announced the initiation of its Phase 1b clinical trial for GT-02287, a lead candidate targeting Parkinsons disease (PD), following regulatory approval in Australia. Read more about the trial aiming to redefine Parkinsons treatment and its potential global impact.
Tags: Biotechnology / Pharmaceuticals

Maryland Biotech Gains Regulatory Approval

Research Report
  ()
Gain Therapeutics Inc. (GANX:NASDAQ) recently received Australian regulatory approval to begin GT-02287 evaluation in Parkinson's disease (PD) patients.
Tags: Biotechnology / Pharmaceuticals

Pharma Co. Signs License Agreement With Boston Medical Center

Research Report
  ()
60 Degrees Pharmaceuticals Inc. (SXTP:NASDAQ) announced a partnership to advance Arakoda (tafenoquine) for babesiosis with Boston-based Tufts Medical Center, according to an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

FDA Expedites Review of Gene Therapy Co.'s Drug

  ()
Clinical stage genetic medicines company MeiraGTx Holdings Plc (MGTX:NASDAQ) says the FDA has granted regenerative medicine advance therapy (RMAT) designation to one of its treatments that could help thousands of patients. Read why one analyst thinks the stock is undersold.
Tags: Biotechnology / Pharmaceuticals

Is This Centrally Positioned AI Healthcare Co. Set to Transform the Industry?

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) offers potential upside to investors.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Medical Equipment Co. Shows Strong Profit Margin

Research Report
  ()
Despite this, the Buy-rated company remains undervalued by the markets due to ongoing business risk, noted a Leede Financial Inc. report.
Tags: Medical Devices

Biopharma Using AI to Find Promising Cancer Drug Candidates

  ()
Biopharmaceutical company Rakovina Therapeutics Inc. (RKV:TSX.V) summarizes its achievements for 2024 and outlines its goals for the coming year. Find out how the company is using AI to accelerate drug development.
Tags: Biotechnology / Pharmaceuticals

New Data Supports BLA Package

Research Report
  ()
Annexon Inc. (ANNX:NASDAQ) recently released real-world evidence data comparing it's ANX005 to standard treatments for Guillain-Barr Syndrome (GBS), according to an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

New Quebec Law Affecting Healthcare Co.'s Bottom Line

Research Report
  ()
Quebec-based staffing operator Premier Health of America Inc. (PHA:TSX.V) reported soft financial data for the fourth quarter of 2024 as the province's Bill 10 act limiting the use of per diem operations. Find out why this analyst thinks things will improve for the company.
Tags: Healthcare Services

Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says

  ()
Clinical-stage biotechnology company Gain Therapeutics Inc.'s (GANX:NASDAQ) drug treating Parkinson's disease could be a "US$4 billion drug," according to one analyst who recently initiated coverage on the Maryland company.
Tags: Biotechnology / Pharmaceuticals

California Biopharma Shows Promising Phase 1 Data

Research Report
  ()
Artelo Biosciences Inc. (ARTL:NASDAQ) recently reported promising Phase 1 results from its CAReS trial evaluating ART27.13 for cancer-related anorexia, according to a D. Boral Capital research note.
Tags: Biotechnology / Pharmaceuticals

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Drug Trial Shows Positive Interim Results for ALS Treatment

  ()
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announced the release of a positive interim analysis of its treatment of Amyotrophic Lateral Sclerosis (ALS). Find out why one analyst says the drug has "potential" to treat the disease and maybe others.
Tags: Biotechnology / Pharmaceuticals

FDA Decision on Drug for Bone Marrow Due Early 2025

Research Report
  ()
The manufacturer sheds light on the amount and remittance schedule of the cash payment it must remit to its partner if the drug gets approved, noted a Leede Financial Inc. report.
Tags: Biotechnology / Pharmaceuticals

Is This California Biopharma Co. In the Right Place at the Right Time?

Research Report
  ()
Roth MKM analyst Dr. Jonathan Aschoff highlighted GT Biopharma Inc.'s (GTBP:NASDAQ) development of unique precision therapeutic agents using camelid-derived nanobodies.
Tags: Biotechnology / Pharmaceuticals

Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative

  ()
Leading regenerative medicine company Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces agreement to explore fighting type I diabetes in Saudi Arabia. Read why one analyst believes the company's technology is "advanced."
Tags: Regenerative MedicineBiotechnology / Pharmaceuticals

Approval Sought in Japan for New Drug to Lower Cholesterol

Research Report
  ()
The U.S. biopharma behind the drug is "pushing for accelerated adoption and expansion into additional territories," noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals